Berenguer Berenguer Juan, González-García Juan
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, España.
Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:37-48. doi: 10.1016/S0213-005X(13)70123-X.
Telaprevir is a new direct-acting antiviral drug for the treatment of hepatitis C virus (HCV) infection and is both a substrate and an inhibitor of cytochrome P450 (CYP450) isoenzymes. With the introduction of this new drug, assessment of drug-drug interactions has become a key factor in the evaluation of patients under treatment for HCV infection. During the treatment of this infection, many patients require other drugs to mitigate the adverse effects of anti-HCV drugs and to control other comorbidities. Moreover, most patients coinfected with HIV and HCV require antiretroviral therapy during treatment for HCV. Physicians should therefore be familiar with the pharmacokinetic properties of direct-acting antivirals for HCV treatment and their potential drug-drug interactions. The present article reviews the available information to date on the interactions of telaprevir with other drugs and provides recommendations for daily clinical practice.
特拉匹韦是一种用于治疗丙型肝炎病毒（HCV）感染的新型直接作用抗病毒药物，它既是细胞色素P450（CYP450）同工酶的底物，也是其抑制剂。随着这种新药的引入，药物相互作用的评估已成为评估接受HCV感染治疗患者的关键因素。在这种感染的治疗过程中，许多患者需要使用其他药物来减轻抗HCV药物的不良反应并控制其他合并症。此外，大多数合并感染HIV和HCV的患者在HCV治疗期间需要抗逆转录病毒疗法。因此，医生应该熟悉用于HCV治疗的直接作用抗病毒药物的药代动力学特性及其潜在的药物相互作用。本文综述了迄今为止有关特拉匹韦与其他药物相互作用的现有信息，并为日常临床实践提供建议。
